Picture EBD Group BIO-Europe 2023 Munich BEU23 650x100px
Organisation › Details

Resalis Therapeutics S.r.l.

Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease. The company is applying its profound understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders. *


Period Start 2021-01-01 established
Products Industry RES-010 (Resalis Therapeutics, antisense oligonucleotide targeting miR-22)
  Industry 2 non-coding RNA
Persons Person Toniolo, Alessandro (Resalis Therapeutics 202302 CEO before Pfizer + Novartis)
  Person 2 Puglisi, Pietro (Claris Ventures 201907 Managing Partner + Co-Founder)
Region Region Torino (Turin) (TO)
  Country Italy
  Street 52 Via Nizza
  City 10126 Torino (TO)
    Address record changed: 2023-03-05
Basic data Employees n. a.
    * Document for »About Section«: Resalis Therapeutics S.r.l.. (2/22/23). "Press Release: Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases". Torino.
Record changed: 2023-07-10


Picture EBD Group Startup Spotlight at BIO-Europe 2023 650x200px

More documents for Resalis Therapeutics S.r.l.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2023 Munich BEU23 650x300px

» top